Product Pipeline

A Pipeline that is Defined by High Unmet Needs and Value

At Processa Pharmaceuticals, we focus on developing drugs that target life-threatening and life-compromising chronic diseases. These drugs are ready, or near ready, for clinical development. We acquire therapies that have demonstrated some clinical or scientific data to support the targeted treatment through studies of the drug itself, an analog of the drug, or a drug with similar pharmacological targets. We then work with the FDA to define a complete development program and out-license the drug before or after the pivotal study. Processa leverages the experience of the team to optimize trial design to create an efficient development program that decreases risk and time for regulatory review with the result of lower cost and quicker access for patients.

Our Portfolio of Pre-Clinical and Clinical Assets with > $1B Market Opportunity


PCS6422 for Metastatic Colorectal Cancer

PCS6422 for Metastatic Colorectal Cancer

We are developing PCS6422 to improve the safety and effectiveness of chemotherapy.

About PCS6422

PCS11T for Various Cancers

PCS11T is a more stable, targeted, patient-friendly alternative to irinotecan, developed to treat colorectal, small cell lung, and pancreatic cancers.

About PCS11T

PCS3117 for Pancreatic Cancer

On June 17, 2021, we entered into a licensing agreement with Ocuphire Pharma, Inc. (NASDAQ: OCUP) to license in RX-3117.  RX-3117 is an oral, anticancer agent with an improved pharmacological profile relative to gemcitabine and other nucleoside analogs. Rx-3117 has a family of patents extending into 2036 as well as U.S. Food and Drug Administration (FDA) Orphan Designation for the treatment of Pancreatic Cancer.  Processa will evaluate the potential benefit of RX-3117 for patients with such cancers as pancreatic or non-small cell lung cancer.

About PCS3117